NICE recommends constipation drug

GPs will have access to a greater variety of treatment options for chronic constipation after NICE approved the drug prucalopride.

In final guidance, NICE recommended prucalopride (Resolor, Movetis) be used to treat some women with chronic constipation, for whom laxatives have not provided adequate relief.

The institute recommends prucalopride should only be offered to women who have tried without relief at least two different types of laxatives from different classes for at least six months, and for whom invasive treatment is being considered.

Professor Peter Littlejohns, clinical and public health director at NICE, said: ‘Chronic constipation, although not life-threatening, can have a significant effect on quality of life, often accompanied by a host of unpleasant symptoms, like irritability, lethargy and painful bloating.

‘We are pleased, therefore, to be able to recommend prucalopride as a clinically and cost effective treatment for some women whose chronic constipation has not been managed with standard laxatives.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

The government has no plans to impose face-to-face appointments targets on general...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

The UK's chief medical adviser has warned that new coronavirus variants may force...

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

The BMA has condemned a £20m weight management enhanced service as 'fundamentally...

GP contract update delivers extra PCN cash and £50m for new enhanced services

GP contract update delivers extra PCN cash and £50m for new enhanced services

An update to the GP contract agreement for 2021/22 has set out details of enhanced...

CQC rejects call for independent review to look at BAME bias in ratings

CQC rejects call for independent review to look at BAME bias in ratings

The CQC has rejected calls for an independent review of its ratings process to look...